Marivic Uychiat
ENSIGN GROUPAbout Marivic Uychiat
Marivic S. Uychiat was appointed to The Ensign Group’s Board effective September 1, 2025, after more than 22 years with the Company; she serves concurrently as Executive Vice President of Clinical Services at Ensign Services, Inc. (since 2016) and is therefore a non‑independent director under Nasdaq rules . She holds a Bachelor’s Degree in Nursing (cum laude) from the University of St. La Salle and completed the Chief Nursing Officer program at UC Irvine’s Paul Merage School of Business . Her board tenure commenced September 1, 2025; ENSG’s 2025 proxy predates her appointment (April 4, 2025) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Ensign Services, Inc. | Executive Vice President, Clinical Services | 2016–present | Senior clinical leadership over skilled nursing/post‑acute care programs |
| The Ensign Group (California ops) | Director of Clinical Services | Beginning 2012 (prior to EVP role) | Oversight of clinical programs in California |
| Vista Knoll Specialized Care | Director of Nursing | Decade‑long tenure (dates not disclosed) | Oversaw psychiatric/neuro‑behavioral, dementia, and short‑term post‑acute rehabilitation care |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| — | — | — | The Company did not disclose any other current public company directorships for Ms. Uychiat in her appointment 8‑K . |
Board Governance
- Committee assignments: Member, Quality Assurance & Compliance (QAC) Committee, alongside Dr. Ann S. Blouin (Chair), Dr. John O. Agwunobi, Mark V. Parkinson, Suzanne D. Snapper, and Barry R. Port .
- Independence: Not independent due to concurrent executive role; Board composition upon her appointment: nine members, six independent and three non‑independent .
- Lead Independent Director: Barry M. Smith .
- Audit and Compensation Committees are comprised of independent directors per Company disclosures .
| Governance Attribute | Detail |
|---|---|
| Board appointment | Effective Sept 1, 2025; term through 2026 annual meeting; expected nomination as Class II director at 2026 meeting for a term ending at the 2027 meeting |
| Committee membership | QAC Committee member |
| Committee chair roles | None disclosed for Ms. Uychiat; QAC chaired by Dr. Ann S. Blouin |
| Independence status | Non‑independent (management) |
| Board composition at appointment | Nine directors; six independent, three non‑independent |
| Lead Independent Director | Barry M. Smith |
Fixed Compensation
Ms. Uychiat will receive her regular employee compensation and “will not receive additional compensation for her board service.” As such, standard non‑employee director cash retainers and equity grants do not apply to her .
| Element | Amount | Notes |
|---|---|---|
| Board cash retainer ($) | $0 | Non‑employee director retainer not applicable to Ms. Uychiat |
| Committee member fees ($) | $0 | No additional compensation for board/committee service |
| Director equity grants ($) | $0 | No additional equity for board service |
For context, the Company’s non‑employee director fee schedule for 2024/2025 was: Board annual retainer $30,000; Audit Chair/Member $30,000/$10,000; QAC Chair/Member $30,000/$6,000; N&CG Chair/Member $12,000/$2,000; Compensation Chair/Member $15,000/$3,000, plus quarterly restricted stock grants under the automatic program (not applicable to employee directors like Ms. Uychiat) .
Performance Compensation
No director performance‑based compensation applies to Ms. Uychiat’s board service (she receives no additional board compensation) .
| Metric | Weight | Threshold | Actual | Payout |
|---|---|---|---|---|
| Not applicable (no director incentive plan) | — | — | — | — |
Other Directorships & Interlocks
| Company | Role | Dates | Committee roles |
|---|---|---|---|
| — | — | — | No other public company directorships disclosed in her appointment filing |
- Interlocks/related‑party: The Company disclosed no arrangements or transactions requiring Item 404(a) related‑party disclosure for Ms. Uychiat at appointment .
Expertise & Qualifications
- Nearly three decades of leadership in skilled nursing and post‑acute care, including clinical program development and policymaking; deep expertise in skilled healthcare management .
- EVP Clinical Services since 2016; previously Director of Clinical Services (California) beginning 2012 .
- Director of Nursing at Vista Knoll Specialized Care for a decade, overseeing complex psychiatric/neuro‑behavioral, dementia, and short‑term rehabilitation populations .
- Education: BSN, cum laude (University of St. La Salle); completed Chief Nursing Officer program (UC Irvine Paul Merage) .
Equity Ownership
- The 8‑K announcing Ms. Uychiat’s appointment does not include equity holdings; ENSG’s 2025 proxy (dated April 4, 2025) predates her board appointment and therefore does not provide a beneficial ownership line for her in that filing .
- Hedging/pledging: Company policy prohibits directors and insider employees from entering into hedging or monetization transactions in Company stock .
Governance Assessment
-
Strengths and positive signals:
- Adds seasoned clinical operator perspective to QAC oversight; QAC chaired by an independent director with healthcare quality credentials (Dr. Blouin) .
- Board remains majority‑independent (six of nine) at the time of her appointment; Audit and Compensation Committees are fully independent, aligning with best practices .
- No related‑party transactions disclosed at appointment, mitigating conflict‑of‑interest risk .
- Strong shareholder support for pay program in prior cycle (Say‑on‑Pay approval ~97.7% at 2024 meeting), suggesting constructive investor‑Board engagement context .
-
Risks/considerations:
- Non‑independent status as a current executive reduces the proportion of independent perspectives on the full Board; however, critical gatekeeper committees (Audit/Compensation) remain independent‑only .
- No board‑specific compensation or equity creates no additional “skin‑in‑the‑game” from board grants; alignment will reflect her existing employee compensation and any existing equity, which were not disclosed in appointment materials .
Independence and conflict check: The Company explicitly states Ms. Uychiat is not independent under Nasdaq rules due to her management role and reports no related‑party transactions requiring disclosure at appointment .